A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy
Authors
Rick Bangs (ORCID: https://orcid.org/0000-0002-0706-8775)
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy
Rick Bangs, Cora Nanette Sternberg, Arash Rezazadeh Kalebasty, Manojkumar Bupathi et al.
Local Database Links
2 links
Journal
Future Oncology
Topics
Bladder and Urothelial Cancer Treatments
article
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy
Rick Bangs, Cora Nanette Sternberg, Arash Rezazadeh Kalebasty, Manojkumar Bupathi, Luke T. Nordquist, Petros D. Grivas, Yohann Loriot, Daniel Peter Petrylak, Huafeng Zhou, Chandler Park, Arjun Vasant Balar, Julia Tonelli, Saby George, Phillip L. Palmbos, Nancy B. Davis, Neeraj Agarwal, Rohit K. Jain, Gurdeep Tagawa
article en
Abstract
No abstract available for this paper.
Publication Tag
Future OncologyVol. 21(23)
Institutions
Roswell Park Comprehensive Cancer Center (US), Vanderbilt University (US), Norton Healthcare (US), University of California, Irvine (US), Cornell University (US), Université Paris-Saclay (FR), University of Michigan (US), Huntsman Cancer Institute (US), Institut Gustave Roussy (FR), University of New Haven (US), NYU Langone Health (US), Fred Hutch Cancer Center (US), University of California, Irvine Medical Center (US), Michigan Medicine (US), Reckitt Benckiser (United States) (US), Rocky Mountain Cancer Centers (US), Bladder Cancer Advocacy Network (US), Nebraska Cancer Specialists (US)